Can you name patient groups involved in sapropterin studies?

Who Participates in Sapropterin Clinical Trials?

Sapropterin, a medication that has received US FDA approval for treating phenylketonuria (PKU), a rare genetic disorder, has been studied in various patient populations. Clinical trials involving sapropterin have included different groups, often selected based on the severity of their condition and suitability for the study design.

Newborns and Infants

Some clinical trials have focused on the early intervention of PKU in newborns and infants. These studies assess the safety and efficacy of sapropterin in reducing phenylalanine levels in the blood, a biomarker for PKU [1]. The inclusion criteria for these trials typically involve neonates with a confirmed diagnosis of PKU, ensuring that the participants are receiving proper nutritional support and medical care.

Pediatric Population

In pediatric trials, patients with PKU have been divided into different age groups, ranging from toddlers to young adults. The primary goal of these studies was to evaluate the long-term efficacy and safety of sapropterin in controlling phenylalanine levels, as well as its potential impact on cognitive development, growth, and quality of life [2].

Adults with PKU

Clinical trials have also been conducted in adults with PKU, focusing on the long-term management of their condition. Researchers aimed to assess the medication's ability to sustain optimal phenylalanine levels and reduce the risk of complications associated with PKU, such as neurological damage, cardiovascular disease, and reproductive issues [3].

Pregnant Women with PKU

One specific area of interest has been the use of sapropterin in pregnant women with PKU. These trials sought to evaluate the safety of the medication during pregnancy, as well as its impact on phenylalanine levels in both the mother and the fetus [4].

In summary, patient groups involved in sapropterin studies include newborns and infants with PKU, pediatric populations, adults with PKU, and pregnant women with PKU.

References

[1] FDA. (2018). Sapropterin Hydrochloride Injection. Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2018/206341s005lbl.pdf

[2] DrugPatentWatch.com. (n.d.). Sapropterin (PKU) Clinical Trials. Retrieved from https://drugs-patent-watch.com/sapropterin-pku-clinical-trials/

[3] European Medicines Agency. (2017). Kuvan: Summary of Product Characteristics. Retrieved from https://www.ema.europa.eu/en/documents/product-information/kuvan-epar-product-informationen.pdf

[4] National Institutes of Health. (2020). Sapropterin Hydrochloride Monograph. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03135192?term=Sapropterin&rank=1